Gastrointestinal bleeding from Dieulafoy’s lesion: Clinical presentation, endoscopic findings, and endoscopic therapy
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Endoscopy
- Vol. 7 (4), 295-307
- https://doi.org/10.4253/wjge.v7.i4.295
Abstract
Although relatively uncommon, Dieulafoy’s lesion is an important cause of acute gastrointestinal bleeding due to the frequent difficulty in its diagnosis; its tendency to cause severe, life-threatening, recurrent gastrointestinal bleeding; and its amenability to life-saving endoscopic therapy. Unlike normal vessels of the gastrointestinal tract which become progressively smaller in caliber peripherally, Dieulafoy’s lesions maintain a large caliber despite their peripheral, submucosal, location within gastrointestinal wall. Dieulafoy’s lesions typically present with severe, active, gastrointestinal bleeding, without prior symptoms; often cause hemodynamic instability and often require transfusion of multiple units of packed erythrocytes. About 75% of lesions are located in the stomach, with a marked proclivity of lesions within 6 cm of the gastroesophageal junction along the gastric lesser curve, but lesions can also occur in the duodenum and esophagus. Lesions in the jejunoileum or colorectum have been increasingly reported. Endoscopy is the first diagnostic test, but has only a 70% diagnostic yield because the lesions are frequently small and inconspicuous. Lesions typically appear at endoscopy as pigmented protuberances from exposed vessel stumps, with minimal surrounding erosion and no ulceration (visible vessel sans ulcer). Endoscopic therapy, including clips, sclerotherapy, argon plasma coagulation, thermocoagulation, or electrocoagulation, is the recommended initial therapy, with primary hemostasis achieved in nearly 90% of cases. Dual endoscopic therapy of epinephrine injection followed by ablative or mechanical therapy appears to be effective. Although banding is reportedly highly successful, it entails a small risk of gastrointestinal perforation from banding deep mural tissue. Therapeutic alternatives after failed endoscopic therapy include repeat endoscopic therapy, angiography, or surgical wedge resection. The mortality has declined from about 30% during the 1970’s to 9%-13% currently with the advent of aggressive endoscopic therapy.Keywords
This publication has 90 references indexed in Scilit:
- Dieulafoy's lesion: current trends in diagnosis and managementThe Annals of The Royal College of Surgeons of England, 2010
- An uncommon cause of life-threatening gastrointestinal bleeding: 2 synchronous Dieulafoy lesionsJournal of Pediatric Surgery, 2009
- Endoscopic Treatment of Dieulafoy Lesions and Risk Factors for RebleedingThe Korean Journal of Internal Medicine, 2009
- Jejunal Dieulafoy lesion with massive lower intestinal bleedingInternational Journal of Colorectal Disease, 2007
- Dieulafoy Lesion: Endoscopic and Surgical ManagementSurgical Laparoscopy, Endoscopy & Percutaneous Techniques, 2006
- Dieulafoy’s lesion and segmental dilatation of the small bowel: An uncommon cause of gastrointestinal bleedingJournal of Pediatric Surgery, 2004
- Adult small bowel Dieulafoy lesionPublished by BMJ ,2001
- Bleeding Dieulafoy's lesions and the choice of endoscopic method: Comparing the hemostatic efficacy of mechanical and injection methodsGastrointestinal Endoscopy, 2000
- Dieulafoy's lesion: an obscure cause of GI bleeding.1999
- THE PATHOGENESIS OF DIEULAFOYS GASTRIC-EROSION1984